Quick Answer
Beta Bionics, Inc. reported R&D Expense of $34.79 million for fiscal year 2025.
Beta Bionics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $34.79M | +32.9% |
| 2024 | $26.18M | +45.9% |
| 2023 | $17.94M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.20M | +59.4% | -7.6% |
| June 30, 2025 | $8.87M | +39.7% | +16.9% |
| March 31, 2025 | $7.59M | +38.5% | +47.6% |
| September 30, 2024 | $5.14M | — | -19.0% |
| June 30, 2024 | $6.35M | — | +15.9% |
| March 31, 2024 | $5.48M | — | — |
- Beta Bionics, Inc. showed an increase of +32.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Beta Bionics, Inc.’s r&d expense has grown by 93.9% (from $17.94 million to $34.79 million).
- The most recent figure is from Beta Bionics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: